(MedPage Today) — Rep. Blake Farenthold (R-Texas) sits down with MedPage Today
Early DSEK improves vision in post-cataract corneal edema
PHILADELPHIA — Early Descemet’s stripping endothelial keratoplasty significantly improved visual acuity in eyes that developed pseudophakic bullous keratopathy after cataract surgery, according to a study presented at the Wills Eye Alumni Conference.“A statistically significant relationship was found between the [corneal edema] to DSEK time and post-DSEK visual acuity. Post-DSEK visual acuity was not associated with the preoperative vision or pachymetry. Performing earlier DSEK for patients with pseudophakic corneal edema may be associated with improved visual outcomes,” Sarah B. Weissbart, MD, said.
FDA proposes powdered glove ban
The FDA has announced a proposal to ban most powdered gloves in the United States, which would effectively remove them from the marketplace, according to a press release issued by the agency.While the FDA acknowledged that use of the gloves is decreasi…
Valeant announces CEO succession plan, financial update
Valeant Pharmaceuticals International announced in a press released that it has initiated a search for a new CEO to succeed J. Michael Pearson and has made changes to its board of directors.Pearson will continue to serve as CEO and a director until a r…
Alimera reports 167% increase in net revenue in 2015
Alimera Sciences reported $22.4 million in consolidated net revenue in 2015, a 167% increase from $8.4 million reported in 2014, according to a press release.Consolidated net revenue was reported at $5.8 million in the fourth quarter, a 241% increase f…
RetroSense Therapeutics Doses First Patient in Phase I/II Clinical Trial for Lead Compound RST-001
ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics LLC, a privately-held biopharmaceutical company, today announced that the first patient has been successfully dosed in the first clinical trial to evaluate the safety of RST-001. The study is t…